Skip Nav Destination
Issues
1 February 2024
-
Cover Image
Cover Image
The cover shows a hematoxylin-and-eosin-stained serous tubal intraepithelial carcinoma, the immediate precursor of ovarian serous carcinoma. Based on a genome-wide aneuploidy study, the authors identified a particular type of precursor lesion showing CCNE1 amplification and high proliferative activity. The microscopic lesions manifest budding, loosely adherent, and detached lesion cells on the surface, a sign portending a potential aggressive clinical behavior. For details, see the article by Wang and colleagues on page 600 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
Tumor-Agnostic Approvals: Insights and Practical Considerations
Chengxing Cindy Lu; Robert A. Beckman; Xiaoyun Nicole Li; Weidong Zhang; Qi Jiang; Olga Marchenko; Zhiping Sun; Hong Tian; Jingjing Ye; Shuai Sammy Yuan; Godwin Yung; on behalf of the Master Protocol subteam of the Statistical Methods in Oncology Scientific Working Group, Biopharmaceutical Session, American Statistical Association
Clinical Trials: Targeted Therapy
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Jeffrey Crawford; Roberto A. Calle; Susie M. Collins; Yan Weng; Shannon L. Lubaczewski; Clare Buckeridge; Ellen Q. Wang; Magdalena A. Harrington; Anil Tarachandani; Michelle I. Rossulek; James H. Revkin
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean; Edith Szafer-Glusman; John F. Seymour
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A. Carneiro; Ludimila Cavalcante; Devalingam Mahalingam; Anwaar Saeed; Howard Safran; Wen Wee Ma; Andrew L. Coveler; Steven Powell; Bruno Bastos; Elizabeth Davis; Vaibhav Sahai; William Mikrut; James Longstreth; Sheri Smith; Taylor Weisskittel; Hu Li; Brittany A. Borden; R. Donald Harvey; Solmaz Sahebjam; Andrés Cervantes; Austin Koukol; Andrew P. Mazar; Neeltje Steeghs; Razelle Kurzrock; Francis J. Giles; Pamela Munster
Clinical Trials: Immunotherapy
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Hans Wildiers; Anne Armstrong; Eveline Cuypere; Florence Dalenc; Luc Dirix; Steve Chan; Frederik Marme; Carolina P. Schröder; Jens Huober; Francois P. Duhoux; Peter Vuylsteke; Agnes Jager; Etienne Brain; Sherko Kuemmel; Zsuzsanna Pápai; Catharina Willemien Menke-van der Houven van Oordt; Luca Perjesi; Christian Mueller; Chrystelle Brignone; Frederic Triebel
Precision Medicine and Imaging
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Lestat R. Ali; Patrick J. Lenehan; Victoire Cardot-Ruffino; Andressa Dias Costa; Matthew H.G. Katz; Todd W. Bauer; Jonathan A. Nowak; Brian M. Wolpin; Thomas A. Abrams; Anuj Patel; Thomas E. Clancy; Jiping Wang; Joseph D. Mancias; Matthew J. Reilley; Chee-Chee H. Stucky; Tanios S. Bekaii-Saab; Rawad Elias; Nipun Merchant; Craig L. Slingluff, Jr; Osama E. Rahma; Stephanie K. Dougan
Translational Cancer Mechanisms and Therapy
Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases
Agata M. Kieliszek; Daniel Mobilio; Deepak Upreti; Darin Bloemberg; Laura Escudero; Jacek M. Kwiecien; Zahra Alizada; Kui Zhai; Patrick Ang; Shawn C. Chafe; Parvez Vora; Chitra Venugopal; Sheila K. Singh
Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
Tamara Codilupi; Jakub Szybinski; Stefanie Arunasalam; Sarah Jungius; Andrew C. Dunbar; Simona Stivala; Sime Brkic; Camille Albrecht; Lenka Vokalova; Julie L. Yang; Katarzyna Buczak; Nilabh Ghosh; Jakob R. Passweg; Alicia Rovo; Anne Angelillo-Scherrer; Dmitry Pankov; Stefan Dirnhofer; Ross L. Levine; Richard Koche; Sara C. Meyer
Modulating Gut Microbiota Prevents Anastomotic Leak to Reduce Local Implantation and Dissemination of Colorectal Cancer Cells after Surgery
Roy Hajjar; Manon Oliero; Gabriela Fragoso; Ayodeji Samuel Ajayi; Ahmed Amine Alaoui; Hervé Vennin Rendos; Annie Calvé; Thibault Cuisiniere; Claire Gerkins; Sophie Thérien; Nassima Taleb; François Dagbert; Herawaty Sebajang; Rasmy Loungnarath; Frank Schwenter; Richard Ratelle; Ramses Wassef; Eric De Broux; Carole Richard; Manuela M. Santos
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds